Interested in implementing an effective multi-scale simulation framework to study key properties of composites? Join us at this year’s Composites and Advanced Materials Expo (CAMX) on Sept 9-12th. • Don’t miss the talk by Schrödinger’s Andrea Browning on Sept 10th to hear real-world case studies exploring efficient computational approaches for materials product design without requiring experimentation or testing. • Check out the panel discussion on Sept 10th to learn how AI-driven innovations can shape the future of materials development. • Stop by our booth G33 to speak with our experts and catch a live demo on Sept 11th highlighting how digital simulation can accelerate your R&D. Learn more: https://hubs.li/Q02MLmmL0 #Schrodinger #MaterialsScience #DigitalChemistry #Polymers
Schrödinger
Software-Entwicklung
New York, New York 46,519 followers
Transforming drug discovery and materials research
Über uns
Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990 and is engaged with customers and collaborators in more than 70 countries. We welcome you to visit our blog at www.extrapolations.com.
- Website
-
http://www.schrodinger.com
External link for Schrödinger
- Industrie
- Software-Entwicklung
- Größe des Unternehmens
- 501-1,000 employees
- Hauptsitz
- New York, New York
- Typ
- Öffentliches Unternehmen
- Gegründet
- 1990
Standorte
Employees at Schrödinger
Aktualisierungen
-
A smart, strategic drug formulation can efficiently advance your drug development projects and inform downstream processes. Cutting-edge molecular modeling and machine learning are enabling atomistic-level insights and the ability to evaluate large numbers of candidate materials and formulations prior to experiments. Join us on Wednesdays this fall for Schrödinger’s Computationally-Guided Drug Formulation Webinar Series – five webinars in which we will explore how the latest computational modeling tools are impacting the pharmaceutical formulation process. Register here: https://lnkd.in/ggg-WkN6
-
-
Schrödinger is pleased to share our recent coverage by Alex Philippidis, released yesterday and available now on Genetic Engineering & Biotechnology News.
Senior Business Editor at Genetic Engineering & Biotechnology News, Inside Precision Medicine and Mary Ann Liebert Inc,
6-7August: What solution is Schrödinger working on to predict the toxicity risk of new drugs early in their development? Hear from President & CEO Ramy Farid, PhD, & Karen Akinsanya, PhD, President of R&D, Therapeutics in my latest for Genetic Engineering & Biotechnology News: https://lnkd.in/ehXQ8bnJ
-
Schrödinger is excited to be participating in the EFMC International Symposium on Medicinal Chemistry taking place on September 1st – 5th in Rome, Italy. Join us for a presentation and workshop by Schrödinger scientists. Learn more: https://hubs.li/Q02KjVX80
-
-
At Schrödinger, we are continuously improving our platform through rigorous scientific advancement. Check out the new features and usability improvements in Schrödinger’s 2024-3 software release: https://lnkd.in/eYix7f2C
-
Schrödinger will announce second quarter 2024 financial results today, July 31, 2024 at 4:30 PM ET. Listen to the LIVE webcast here: https://lnkd.in/d3baFfsM
-
-
Schrödinger is excited to be participating in the 8th International Conference on Vibrational Optical Activity taking place August 4-8 in Bochum, Germany. Join us for a presentation by Art Bochevarov, Research Leader at Schrödinger, in which he will discuss the latest tools and algorithms Schrödinger has developed to aid in the selection of conformers for VCD spectra prediction, including Jaguar Spectroscopy. Learn more: https://hubs.li/Q02Jk6xY0
-
-
Today, Schrödinger announced a new initiative leveraging our computational platform to predict toxicology risk early in drug discovery. Initially funded by a $10 million grant from the Bill & Melinda Gates Foundation and enabled by NVIDIA’s AI technologies, the initiative aims to improve properties of novel drug development candidates and reduce their risk of binding to off-target proteins, which can be associated with serious side effects and lead to failure of the development program. Learn more about the new initiative in our press release: https://hubs.li/Q02J2Nmq0
-
-
AI/ML models are powerful tools for predicting diverse physical and chemical properties of small molecules. However, fine-tuning these models is resource-intensive and challenging to scale for numerous, frequently updated datasets. Join us on August 13th for a webinar introducing Schrödinger’s LiveDesign Learning, a new module in LiveDesign for training and deploying state-of-the-art AI/ML models with minimal manual intervention to offer rapid molecular property predictions. Register now: https://lnkd.in/g6QMpEkg
-